CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 74 enrolled
Drug / intervention
Lidocaine Hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03854344
NCT03854344Phase 4Completed
CompareCT.gov

Prospective Study of Liposomal Bupivacaine for Pain Control of Split Thickness Skin Graft Donor Sites

University of Kansas Medical Center·interventional·Posted Feb 26, 2019·Updated Mar 31, 2026

In Brief

A Phase 4 clinical trial evaluating Lidocaine Hydrochloride, Liposomal bupivacaine, and 1 other intervention for Pain, Postoperative and Burns. Completed, enrolled 74 participants across 1 site.

Detailed Summary

Donor site pain study comparing post-operative donor site pain and opioid consumption after use of Lidocaine, Liposomal Bupivicaine or regional nerve block for split thickness skin graft harvesting in patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness burn wounds.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative, Burns
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedFeb 26, 2019
Enrollment StartMar 18, 2019
Primary CompletionAug 6, 2025
Study CompletionOct 27, 2025
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 7.4 years ago

Interventions

Lidocaine Hydrochloridedrug

Injected subcutaneously for skin graft harvesting

Liposomal bupivacainedrug

Injected subcutaneously for skin graft harvesting

Bupivacaine Hydrochloridedrug

Used for regional nerve block for skin graft harvesting